Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline Effects on Smoking Lapse in Schizophrenia
NCT01850953Phase 4Completed
- Sponsor
- Center for Addiction and Mental Health
- Start
- Jun 2013
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of varenicline in nicotine dependence, sponsored by Center for Addiction and Mental Health. Primary endpoint: Time to Smoking Lapse at Day 6. Started Jun 2013; status: completed.
02
Drugs
varenicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT01850953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01850953.